Healthcare News by GLG Council Members
Analyses are solely the work of the authors and have not been edited or endorsed by GLG.
-
Saxagliptin - third gliptin on the EU market
October 8, 2009
ONGLYZA™ (saxagliptin) Receives Marketing Authorisation In Europe For The Treatment Of Type 2 Diabetes | www.pipelinereview.com
Besides Sitagliptin and Vildagliptin there will be now a 3rd gliptin available in Europe. Whereas vildagliptin officially needs monitoring of the liver enzymes, at least according to the P.I., and there are new warnings for pancreatitis for sitagliptin no such limitations are known to me at the moment. I do not think that there will be major advantages for saxa compared with sita or vilda, however, we will have to wait and see.
-
Ken PowellPresidentGenesis Business Development, LLC
CDC Outlines H1N1 Test Guidelines
October 8, 2009
CDC Releases Interim Guidelines for Using H1N1 Tests | www.genomeweb.com
The Centers for Disease Control and Prevention released interim guidelines for H1N1 (swine flu) testing. The guidelines include the four clinical diagnostic methods used to test for H1N1. The tests vary in their ability to differentiate flu types, sensitivity, specificity and turnaround time for results.
-
Ken PowellPresidentGenesis Business Development, LLC
Clinical Labs Could Benefit from New Legislation
October 8, 2009
Clinical Molecular Dxs Shine in Revised Senate Bill; Clinical Labs ‘Potential Winners’ | news.google.com
A new revision to the Senate Finance Committee health care proposal could benefit clinical labs that provide key diagnostic tests. These include companies such as Quest Diagnostics, LabCorp and Bio-Reference Laboratories.
-
Ken PowellPresidentGenesis Business Development, LLC
October 7, 2009
Gen-Probe to Acquire Prodesse for at Least $60M | www.genomeweb.com
Gen-Probe, one of the leading worldwide clinical diagnostic companies has announced an agreement to acquire privately held Prodesse. This strategic move expands Gen-Probe's molecular diagnostics infectious disease portfolio and solidly positions the company in this high growth clinical diagnostics market segment.
-
Ken PowellPresidentGenesis Business Development, LLC
Thermo Fisher Could Benefit From Consolidation
October 7, 2009
Thermo Fisher Scientific to Close Dubuque Facility, Lay Off 350 | www.genomeweb.com
Thermo Fisher set a fast acquisition pace over the past few years. The recent announcements to close facilities in Dubuque, Iowa and Hudson, NH are signs that the company is now implementing moves to benefit from the proposed synergies of their strategic acquisitions.
-
NO BRAINER: Genentech Prefers to Promote Lucentis over Avastin for Wet ARMD
October 7, 2009
Genentech revisits plan for Avastin | www.sfgate.com
It does not require a lot of ophthalmic and business savy to understand why a company rather promote a drug that costs more than 20 times more to treat the same medical condition.
-
Sandoz’ Generic Drug Push in Japan: Good Timing; Interesting Challenges
October 7, 2009
Sandoz Plans to Sell More Drugs in Japan, May Acquire Companies | www.bloomberg.com
Novartis AG's generic pharmaceutical unit, Sandoz AG's timing for entry into the Japanese pharmaceutical market is excellent as seismic forces in the market make generic drugs more attractive than ever. Sandoz CEO Jeff George's challenges include a prestige-driven hospital system and a private practice/physician medical practice that rewards branded pharmaceuticals. But Sandoz and Novartis could capitalize on some crucial allies in their fight.
-
Ken PowellPresidentGenesis Business Development, LLC
Cepheid Expects H1N1 FDA Approval
October 7, 2009
Cepheid Eyes EUA from FDA for H1N1 Test | www.genomeweb.com
Cepheid has applied for an Emergency Use Approval (EUA) from the FDA for its molecular H1N1 (swine flu) test. Molecular based tests have been shown to be more accurate than rapid lateral flow assays available marketed by several manufacturers.
-
Ken PowellPresidentGenesis Business Development, LLC
Merck and Qiagen Team Up to Fight HPV
October 7, 2009
Qiagen, Merck Team on HPV Dx, Rx in Developing World | www.genomeweb.com
Merck and Qiagen (NASDAQ: QGEN) have entered into a synergistic collaboration to combat HPV (human papilloma virus) in developing countries. The collaboration calls for Qiagen to provide its Digene HC2 HPV DNA Test and a new HPV DNA test that is still under development, while Merck will provide its Gardasil vaccine for HPV Types 6, 11, 16, and 18.
-
Ken PowellPresidentGenesis Business Development, LLC
Qiagen's Acquisition Expands High Value Diagnostics Position
October 7, 2009
Qiagen Acquires UK's DxS in Deal Worth up to $130M | www.genomeweb.com
Qiagen's recent acquisition of the UK company DxS expands its position in providing integrated diagnostic tests that provide high value results. This particular acquisition could provide Qiagen with the opportunity to build a leadership position in the high growth, personalized medicine segment of the IVD industry.
- Subscribe to Updates
-
Leading institutions connect with members of the Healthcare councils through GLG
Get Intelligently Connected
with the world's leading experts
GLG's 850+ Clients Include:
- More than 70% of the world's leading
- mutual funds
- 15 of the leading 20
- global banks
- 7 of the leading 10
- global private equity firms
- 5 of the leading 10
- AmLaw firms
- Fortune 500® Companies
- in nearly every industry sector, including pharmaceuticals, insurance, chemicals, energy and computer software
Most Popular Healthcare News
-
What is potential future for Sequenom in prenatal testing.
November 9, 2009
-
November 7, 2009
-
Express Scripts feeling Growing Pains
October 29, 2009
-
CDC Outlines H1N1 Test Guidelines
October 8, 2009
-
Why Health Care Costs Keep Rising—And What to Do About It
September 13, 2009